Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Dyadic International (NQ: DYAI ) 1.460 -0.070 (-4.58%) Streaming Delayed Price Updated: 12:54 PM EDT, Jul 2, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Dyadic International < Previous 1 2 3 4 Next > Dyadic to Report Second Quarter 2022 Financial Results on Wednesday, August 10, 2022 July 27, 2022 From Dyadic International, Inc. Via GlobeNewswire Dyadic Reports Second Quarter 2021 Financial Results and Highlights Recent Company Progress August 12, 2021 - Executed binding term sheet with Sorrento Therapeutics (Nasdaq:SRNE) to outlicense C1 protein production platform for the development and commercialization of vaccines, therapeutic antibodies,... From Dyadic International, Inc. Via AccessWire Topics Regulatory Compliance Supply Chain Exposures COVID-19 Legal Regulatory Dyadic to Report Second Quarter 2021 Financial Results July 29, 2021 JUPITER, FL / ACCESSWIRE / July 29, 2021 / Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving,... From Dyadic International, Inc. Via AccessWire Topics Regulatory Compliance Exposures Legal Regulatory Dyadic to Present at Upcoming Events May 24, 2021 JUPITER, FL / ACCESSWIRE / May 24, 2021 / Dyadic International, Inc. ("Dyadic", or the "Company") (NASDAQ:DYAI) a global biotechnology company focused on further improving, applying and deploying its... From Dyadic International, Inc. Via AccessWire Exposures COVID-19 Dyadic Reports First Quarter 2021 Financial Results and Highlights Recent Company Progress May 13, 2021 - Advancing Dyadic's proprietary COVID-19 vaccine candidate, DYAI-100, towards a first-in-human Phase 1 clinical trial - Goal of validating that C1 produced proteins are safe in humans and to... From Dyadic International, Inc. Via AccessWire Topics Intellectual Property Regulatory Compliance Exposures COVID-19 Intellectual Property Legal Dyadic to Report First Quarter 2021 Financial Results April 29, 2021 JUPITER, FL / ACCESSWIRE / April 29, 2021 / Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving,... From Dyadic International, Inc. Via AccessWire Topics Regulatory Compliance Exposures Legal Regulatory < Previous 1 2 3 4 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.